Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Texans are in store for another hot week. Is there an ideal thermostat temperature that balances comfort and affordability?

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

A pair of FDA-approved cancer drugs may help reverse the biological changes that drive Alzheimer’s disease, according to a ...

An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers ...

About 20 million Americans have macular degeneration – a condition that damages vision and can cause blindness. Now, a doctor ...

Alongside lasers, Lithuania has expertise in bio-technology, particularly CRISPR, a niche skill that got Jennifer Doudna and ...

There are currently estimated to be 982,000 people with some form of dementia, including Alzheimer's in the UK ...

Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...